Hereditary Ovarian Cancer and Other Gynecologic Malignancies

2010 ◽  
pp. 181-196
Author(s):  
Kathryn R. Brown ◽  
Lynn P. Parker
2011 ◽  
Vol 152 (40) ◽  
pp. 1596-1608 ◽  
Author(s):  
József Gábor Joó ◽  
Szabolcs Ládi ◽  
B. Zsolt Nagy ◽  
Zoltán Langmár

Mutations in BRCA1 and BRCA2 genes account for the majority of hereditary breast and ovarian cancers. Approximately 10% of cases of ovarian cancer are due to germline mutations in BRCA1 and BRCA2. Ovarian cancer associated with BRCA1 and BRCA2 mutations has a distinct histological phenotype. This type of cancer is predominantly of serous or endometrioid histology and is high grade. Patients with BRCA1 or BRCA2 mutations should be offered risk-reducing salpingo-oophorectomy by age 40 years, or when childbearing is complete. Nowadays there are no differences between the treatments provided for sporadic and hereditary ovarian cancer, although there are indications that targeted therapy is effective in women with BRCA1/BRCA2-associated tumors. Retrospective studies reveal a high level of sensitivity to platinum agents in BRCA-associated tumors and initial trials show good efficacy and tolerability for polyADP-ribose polymerase inhibitors in mutation carriers with advanced ovarian cancers. These agents might also potentially be used in chemoprevention. Authors review the current management of hereditary ovarian cancer. Orv. Hetil., 2011, 152, 1596–1608.


1997 ◽  
Vol 9 (1) ◽  
pp. 3-7 ◽  
Author(s):  
Amelia A. Langston ◽  
Elaine A. Ostrander

2019 ◽  
Vol 32 (Suppl 2) ◽  
Author(s):  
Jana Soukupová ◽  
Klára Lhotová ◽  
Petra Zemánková ◽  
Michal Vočka ◽  
Markéta Janatová ◽  
...  

2019 ◽  
Vol 25 (4) ◽  
pp. 365 ◽  
Author(s):  
Sang Hee Lee ◽  
Hyangkyu Lee ◽  
Myong Cheol Lim ◽  
Sue Kim

Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Michelle R. Jacobson ◽  
Melissa Walker ◽  
Gabrielle E.V. Ene ◽  
Courtney Firestone ◽  
Marcus Q. Bernardini ◽  
...  

2010 ◽  
Vol 1 (1) ◽  
pp. 67-79
Author(s):  
Mary E. Gordinier ◽  
Carol L. Hanchette

From 1995-2005, ovarian cancer accounted for 2.7% of new cancer cases diagnosed among women in Kentucky and was responsible for 4.7% of female cancer deaths in the state. The five-year survival rate for ovarian cancer is 45% for all stages combined. Multiple studies document a survival advantage for women with gynecologic malignancies when treated by a gynecologic oncologist. The authors used Kentucky Cancer Registry data for the years 1995-2005, geocoded to 5-digit ZIP code, to examine the hypothesis that ovarian cancer survival is higher among patients receiving treatment in areas where gynecologic oncologists practice. Their hypothesis was confirmed. A secondary goal of the study was to identify geographic areas of the state with lower overall access to care. Contrary to the expected pattern of low access to care in the Appalachian region of the state, their analysis indicated that access to successful treatment is a greater issue in the western portion of Kentucky.


Author(s):  
Marian J. Mourits ◽  
G. H. de Bock

The history of screening and prevention of ovarian cancer among high-risk women in the United States and Europe is one of mutual inspiration, with researchers learning from each others’ findings and insights and collaborating with investigators from both sides of the Atlantic ocean. Examples of simultaneous and joint development of knowledge and scientific points of view include the paradigm shift from ovarian to fallopian tube high-grade serous cancer and the cessation of simultaneous adoption of ovarian cancer screening by clinicians in both the United States and Europe. Examples of joint efforts with fruitful results include international collaboration in large population-based, genome-wide association studies and in epidemiologic database studies. Research in the field of hereditary ovarian cancer is a great example of mutual inspiration and joint efforts for the purpose of improving knowledge and health care for women with hereditary ovarian cancer.


2019 ◽  
Vol 154 ◽  
pp. 272
Author(s):  
L. Li ◽  
X. Meng ◽  
C. Lin ◽  
D. Shao ◽  
Y. Xiong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document